Eterna Therapeutics

ERNA

Market cap $5.19M

ERNA Hedge Fund Activity: Q1 2026 in Review

15 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2026, worth a combined $711K — down 38% from $1.15M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ERNA positions and 4 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Bleichroeder LP, opening a new position worth an estimated $1.28M. The largest seller was Corient Private Wealth, cutting an estimated $280K.

• 15 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2026, up from 11 in Q4 2025.
• Funds reported $711K of Eterna Therapeutics stock for Q1 2026, down 38% quarter-over-quarter.
• 9 funds opened new Eterna Therapeutics positions in Q1 2026 and 4 closed out, a net change of +5 holders.
• The largest Eterna Therapeutics buyer in Q1 2026 was Bleichroeder LP, an estimated $1.28M added.
• The largest Eterna Therapeutics seller in Q1 2026 was Corient Private Wealth, an estimated $280K sold.

Based on aggregated 13F filings for Q1 2026.